HUP0402370A3 - Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination - Google Patents

Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination

Info

Publication number
HUP0402370A3
HUP0402370A3 HU0402370A HUP0402370A HUP0402370A3 HU P0402370 A3 HUP0402370 A3 HU P0402370A3 HU 0402370 A HU0402370 A HU 0402370A HU P0402370 A HUP0402370 A HU P0402370A HU P0402370 A3 HUP0402370 A3 HU P0402370A3
Authority
HU
Hungary
Prior art keywords
inhibitor
cyclooxigenase
pharmaceutical compositions
compositions containing
histone deacetylase
Prior art date
Application number
HU0402370A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0402370A2 publication Critical patent/HUP0402370A2/hu
Publication of HUP0402370A3 publication Critical patent/HUP0402370A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU0402370A 2001-11-06 2002-11-05 Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination HUP0402370A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17
PCT/EP2002/012343 WO2003039599A1 (en) 2001-11-06 2002-11-05 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Publications (2)

Publication Number Publication Date
HUP0402370A2 HUP0402370A2 (hu) 2005-02-28
HUP0402370A3 true HUP0402370A3 (en) 2008-04-28

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402370A HUP0402370A3 (en) 2001-11-06 2002-11-05 Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination

Country Status (22)

Country Link
US (3) US7402603B2 (hu)
EP (1) EP1443967B1 (hu)
JP (1) JP4413614B2 (hu)
KR (1) KR100937064B1 (hu)
CN (1) CN100457183C (hu)
AT (1) ATE352319T1 (hu)
AU (1) AU2002351844B2 (hu)
BR (1) BR0213932A (hu)
CA (1) CA2461373A1 (hu)
CY (1) CY1106508T1 (hu)
DE (1) DE60217895T2 (hu)
DK (1) DK1443967T3 (hu)
ES (1) ES2280597T3 (hu)
HU (1) HUP0402370A3 (hu)
IL (2) IL160970A0 (hu)
MX (1) MXPA04004312A (hu)
NO (1) NO20042148L (hu)
NZ (1) NZ544689A (hu)
PL (1) PL205853B1 (hu)
PT (1) PT1443967E (hu)
RU (1) RU2311200C2 (hu)
WO (1) WO2003039599A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) * 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
MX2008015898A (es) 2006-06-12 2009-01-12 Novartis Ag Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma.
AU2007257882B2 (en) * 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
MY149337A (en) * 2006-06-12 2013-08-30 Novartis Ag Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
MX2008016503A (es) * 2006-06-28 2009-06-08 Novartis Ag Uso de inhibidores de hdac para el tratamiento de linfomas.
EP2055692A4 (en) * 2006-08-25 2010-07-07 Asahi Glass Co Ltd PROCESS FOR PRODUCING 1,2-DIALCOXY-3-FLUOROBENZENE
AU2008214299B2 (en) 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2008100985A2 (en) * 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
EP2200439B1 (en) 2007-10-01 2017-03-22 Lixte Biotechnology, Inc. Hdac inhibitors
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
EP2840076B1 (en) * 2012-04-16 2017-10-25 TOA Eiyo Ltd. Bicyclic compound
BR112015025852A2 (pt) 2013-04-09 2017-07-25 Lixte Biotechnology Inc as formulações de oxabicicloheptanos e oxabicicloheptenos
MA41677A (fr) 2015-03-13 2021-06-02 Forma Therapeutics Inc Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
EP1443967B1 (en) 2007-01-24
BR0213932A (pt) 2004-08-31
US20080227845A1 (en) 2008-09-18
NO20042148L (no) 2004-08-04
HUP0402370A2 (hu) 2005-02-28
PL368539A1 (en) 2005-04-04
PT1443967E (pt) 2007-04-30
RU2004117170A (ru) 2005-04-20
CN1578674A (zh) 2005-02-09
KR20050043744A (ko) 2005-05-11
KR100937064B1 (ko) 2010-01-15
DE60217895D1 (en) 2007-03-15
IL160970A (en) 2010-06-30
JP2005510517A (ja) 2005-04-21
EP1443967A1 (en) 2004-08-11
MXPA04004312A (es) 2005-05-16
DK1443967T3 (da) 2007-04-16
ATE352319T1 (de) 2007-02-15
US20090192211A1 (en) 2009-07-30
CY1106508T1 (el) 2012-01-25
CN100457183C (zh) 2009-02-04
DE60217895T2 (de) 2007-07-05
CA2461373A1 (en) 2003-05-15
WO2003039599A1 (en) 2003-05-15
JP4413614B2 (ja) 2010-02-10
AU2002351844B2 (en) 2006-12-21
PL205853B1 (pl) 2010-06-30
IL160970A0 (en) 2004-08-31
US7402603B2 (en) 2008-07-22
ES2280597T3 (es) 2007-09-16
RU2311200C2 (ru) 2007-11-27
US20050032899A1 (en) 2005-02-10
NZ544689A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
HUP0402370A3 (en) Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination
HUS1500068I1 (hu) Dezacetiláz inhibitor hatású hidroxamát származékok és ezeket tartalmazó gyógyszerkészítmények
AU2002243402A1 (en) Inhibitors of histone deacetylase
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
HUP0202707A3 (en) Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and pharmaceutical compositions containing them and use thereof
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
HUP0303193A3 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them
IL164006A0 (en) Inhibitors of histone deacetylase
HK1072365A1 (en) Inhibitors of histone deacetylase
HUS1400025I1 (hu) Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
KR100984939B9 (ko) 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
HUP0500173A3 (en) Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0301472A3 (en) Carbamate caspase inhibitors and uses thereof and pharmaceutical compositions containing them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0400328A3 (en) Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them
HUP0400668A3 (en) Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
HUP0401582A3 (en) Pharmaceutical compositions containing combination of nsaid and pde-4 inhibitors and their use
HRP20041079A2 (en) Novel perindopril salt and pharmaceutical compositions containing same
IL158671A0 (en) Benzyloxy derivatives and pharmaceutical compositions containing the same
GB0226855D0 (en) Histone deacetylase inhibitors
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL159591A0 (en) Pharmaceutical compositions containing terbinafin and use thereof
GB0005199D0 (en) Modulation of histone deacetylase
HUP0401596A3 (en) Cross-linked glycopeptide-cephalosporin antibiotics and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees